New York, NY (PRWEB) February 26, 2014
As testosterone lawsuits (http://www.testosteronelawsuitcenter.com/ ) involving AndroGel continue to mount, Bernstein Liebhard LLP notes that a leading consumer advocacy group is pushing federal regulators to add new safety warnings to the labeling for this class of medication. According to a CBS News report, Public Citizen has filed petition with the U.S. Food & Drug Administration (FDA) asserting that black box warnings, the most serious label warnings possible, are urgently needed to inform the public about the possible association between low testosterone therapies and heart attacks and other serious cardiovascular side effects. *
“Since the FDA announced it was investigating the heart risks potentially associated with testosterone drugs, we have received a number of testosterone lawsuit inquiries from men who allegedly suffered heart attacks and other cardiovascular problems while using these medications,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal reviews to anyone who may have suffered serious heart attacks, strokes, deep vein thrombosis or pulmonary embolism, allegedly due to the use of prescription testosterone therapies.
Testosterone Treatment Lawsuits
On January 31, 2014, the FDA announced it was reviewing the heart risks that may be associated with this class of medications after two studies found a high rate of serious cardiovascular events in men with preexisting heart problems who received testosterone. The FDA has not yet concluded that these drugs will raise the risk of such heart events, but has advised doctors to weigh their risk and benefits when they are prescribed.
Since the FDA announcement, court documents show that a number of testosterone lawsuits have been filed in the Northern District of Illinois on behalf of men who were allegedly injured by AndroGel. These include four cases filed on February 4th which allege the medication caused plaintiffs to suffer heart attacks, strokes and heart failure. (Case Nos: 1:14-cv-00776, 1:14-cv-00780, 1:14-cv-00777, and 1:14-cv-00772) A Fifth AndroGel lawsuit filed on February 10th claims that the plaintiff suffered pulmonary embolism, deep vein thrombosis, and other serious cardiovascular injuries after using multiple doses of the drug. (Case: 1:14-cv-00917)
Men who have suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism or other serious heart problems allegedly due to the use of low testosterone therapy may be entitled to compensation for their injuries. To learn more about filing a testosterone lawsuit, please visit Bernstein Liebhard LLP’s website. To obtain a free review of your case, please call 800-511-5092.
*cbsnews.com/news/group-asks-fda-for-black-box-warning-on-testosterone-products-due-to-heart-risks/, CBS News, February 25, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com